Address
55 Collins Street
Melbourne, VIC 3000
Australia
Phone
61 3 9639 6036
Website
Sector
Healthcare
Industry
Biotechnology
Employees
73
First IPO Date
January 20, 2010
| Name | Title | Pay | Year Born |
| Silviu Itescu FACP FACRA FRACP MBBS | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director | 1.68M | 1957 |
| Paul J. Simmons | Scientific Advisor to the Chief Executive Officer | 0 | 1959 |
| Eric A. Rose | Chief Medical Officer & Executive Director | 894,275 | 1951 |
| Fiona See | Senior Vice President & Head of Translational Research | 0 | N/A |
| Daniel Devine | Head of Special Projects | 0 | N/A |
| James Michael O'Brien | Chief Financial Officer | 0 | 1966 |
| Justin Horst | Head of Manufacturing | 0 | N/A |
| Marcelo Santoro | Chief Commercial Officer | 0 | N/A |
| Paul Hughes BPHARM | Global Head of Corporate Communications & Joint Company Secretary | 0 | N/A |
| Peter T. Howard | General Counsel & Corporate Executive | 0 | 1968 |
| Geraldine Storton | Head of Regulatory Affairs & Quality Management | 0 | N/A |
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.